May 2026
1. VAFAI SB, Taubel J, Ashdown T, Patel RS, et al
   In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.
   N Engl J Med. 2026 May 25. doi: 10.1056/NEJMoa2601283.
   

   >> Share

   
   April 2026
2. MARSTON NA, Bergmark BA, Sabatine MS
   Olezarsen for Hypertriglyceridemia and Pancreatitis Risk. Reply.
   N Engl J Med. 2026;394:1763-1764.
   

   >> Share

   
   
3. WANG S, Fan Z
   Olezarsen for Hypertriglyceridemia and Pancreatitis Risk.
   N Engl J Med. 2026;394:1763.
   

   >> Share

   
   
4. CHEN R, Lu S, Chen M
   Olezarsen for Hypertriglyceridemia and Pancreatitis Risk.
   N Engl J Med. 2026;394:1762.
   

   >> Share

   
   February 2026
5. NAVAR AM, Mikhailova E, Catapano AL, Banka P, et al
   A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.
   N Engl J Med. 2026;394:529-539.
   

   >> Share

   
   
6. SCHUNKERT H, Natarajan P, Samani NJ
   The Inherited Basis of Coronary Artery Disease.
   N Engl J Med. 2026;394:576-587.
   

   >> Share

   
   January 2026
7. MORRIS PB
   CORE Principles in the Management of Severe Hypertriglyceridemia.
   N Engl J Med. 2026;394:509-510.
   

   >> Share

   
   
8. BERGMARK BA, Marston NA, Sabatine MS
   Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. Reply.
   N Engl J Med. 2026;394:99.
   

   >> Share

   
   
9. TOMLINSON B
   Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.
   N Engl J Med. 2026;394:99.
   

   >> Share

   
   
10. PERLEMUTER G, Voican C
    Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.
    N Engl J Med. 2026;394:98-99.
    

    >> Share

    
    November 2025
11. LAFFIN LJ, Nicholls SJ, Scott RS, Clifton PM, et al
    Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.
    N Engl J Med. 2025;393:2119-2130.
    

    >> Share

    
    
12. MARSTON NA, Bergmark BA, Alexander VJ, Prohaska TA, et al
    Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.
    N Engl J Med. 2025 Nov 8. doi: 10.1056/NEJMoa2512761.
    

    >> Share

    
    August 2025
13. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
    Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.
    N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2507227.
    

    >> Share

    
    July 2025
14. MCFARLAND R, Hyslop LA, Feeney C, Pillai RN, et al
    Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease.
    N Engl J Med. 2025;393:461-468.
    

    >> Share

    
    May 2025
15. NICHOLLS SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, et al
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
    N Engl J Med. 2025 May 7. doi: 10.1056/NEJMoa2415820.
    

    >> Share

    
    March 2025
16. MAGNUSSEN C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, et al
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025 Mar 30. doi: 10.1056/NEJMoa2415879.
    

    >> Share

    
    September 2024
17. WATTS GF, Rosenson RS, Hegele RA, Goldberg IJ, et al
    Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk.
    N Engl J Med. 2024 Sep 2. doi: 10.1056/NEJMoa2409368.
    

    >> Share

    
    August 2024
18. FABBRINI E, Rady B, Koshkina A, Jeon JY, et al
    Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD.
    N Engl J Med. 2024;391:475-476.
    

    >> Share

    
    May 2024
19. ROSENSON RS, Gaudet D, Hegele RA, Ballantyne CM, et al
    Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.
    N Engl J Med. 2024 May 29. doi: 10.1056/NEJMoa2404147.
    

    >> Share

    
    
20. BALLANTYNE CM, Vasas S, Azizad M, Clifton P, et al
    Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.
    N Engl J Med. 2024 May 28. doi: 10.1056/NEJMoa2404143.
    

    >> Share

    
    April 2024
21. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
    Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2402309.
    

    >> Share

    
    
22. WATTS GF
    Shooting the Messenger to Treat Hypertriglyceridemia.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMe2402653.
    

    >> Share

    
    
23. STROES ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, et al
    Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2400201.
    

    >> Share

    
    February 2024
24. ALEXANDER VJ, Karwatowska-Prokopczuk E, Prohaska TA, Li L, et al
    Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia.
    N Engl J Med. 2024;390:476-477.
    

    >> Share

    
    April 2023
25. ALEXANDER JH
    Benefits of Bempedoic Acid - Clearer Now.
    N Engl J Med. 2023;388:1425-1426.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share